Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1985 Dec;62(3):474–481.

BCG-induced suppressor T cells optimal conditions for in vitro induction and mode of action.

A S Mustafa, T Godal
PMCID: PMC1577490  PMID: 2935339

Abstract

In vitro activation with BCG of T cells from healthy individuals vaccinated with BCG lead to the induction of suppressor cells that suppressed the proliferation of fresh T cells in response to specific antigen. Kinetics of their induction revealed that they became radioresistant by day 8 and persisted up to 18 days of the culture period. Optimal antigen and monocyte concentrations as assessed by proliferation during the induction phase also resulted in maximum suppression. The strongest suppressor activity was observed when suppressor cells were added at an early time of fresh cell activation. IL-1 production from adherent cells in response to BCG was not affected, but, IL-2 production by T-cells was considerably reduced in the presence of suppressor cells. IL-1 containing supernatants and affinity purified IL-1 exogenously added to the culture system did not affect suppression. Whereas, recombinant IL-2 partially abrogated suppression in a dose-dependent manner. Further experiments suggested that suppressor cells might have inhibited BCG induced IL-2 receptor expression on fresh T cells.

Full text

PDF
474

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bechelli L. M., Garbajosa P. G., Gyi M. M., Uemura K., Sundaresan T., Martínez Domínguez V., Matejka M., Tamondong C., Quagliato R., Engler V. BCG vaccination of children against leprosy: seven-year findings of the controlled WHO trial in Burma. Bull World Health Organ. 1973;48(3):323–334. [PMC free article] [PubMed] [Google Scholar]
  2. Brandely M., Hurtrel B., Lagrange P. H. Comparison between immunopotency tests and specific active or passive acquired resistance against Mycobacterium tuberculosis in mice induced with three different preparations of BCG pasteur vaccine. Clin Exp Immunol. 1983 Oct;54(1):143–150. [PMC free article] [PubMed] [Google Scholar]
  3. Cantrell D. A., Smith K. A. The interleukin-2 T-cell system: a new cell growth model. Science. 1984 Jun 22;224(4655):1312–1316. doi: 10.1126/science.6427923. [DOI] [PubMed] [Google Scholar]
  4. Comstock G. W., Webster R. G. Tuberculosis studies in Muscogee County, Georgia. VII. A twenty-year evaluation of BCG vaccination in a school population. Am Rev Respir Dis. 1969 Dec;100(6):839–845. doi: 10.1164/arrd.1969.100.6.839. [DOI] [PubMed] [Google Scholar]
  5. Dos Reis G. A., Shevach E. M. Effect of cyclosporin A on T cell function in vitro: the mechanism of suppression of T cell proliferation depends on the nature of the T cell stimulus as well as the differentiation state of the responding T cell. J Immunol. 1982 Dec;129(6):2360–2367. [PubMed] [Google Scholar]
  6. Feldmann M., Kontiainen S. Suppressor cell induction in vitro. II. Cellular requirements of suppressor cell induction. Eur J Immunol. 1976 Apr;6(4):302–305. doi: 10.1002/eji.1830060413. [DOI] [PubMed] [Google Scholar]
  7. Godal T., Lindmo T., Marton P. F., Landaas T. O., Langholm R., Høie J., Foss Abrahamsen A. Immunological subsets in human B-cell lymphomas. Scand J Immunol. 1981 Nov;14(5):481–492. [PubMed] [Google Scholar]
  8. Kvaløy S., Langholm R., Kaalhus O., Michaelsen T., Funderud S., Foss Abrahamsen A., Godal T. Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomas. Int J Cancer. 1984 Feb 15;33(2):173–177. doi: 10.1002/ijc.2910330204. [DOI] [PubMed] [Google Scholar]
  9. Larsson E. L., Iscove N. N., Coutinho A. Two distinct factors are required for induction of T-cell growth. Nature. 1980 Feb 14;283(5748):664–666. doi: 10.1038/283664a0. [DOI] [PubMed] [Google Scholar]
  10. Leonard W. J., Depper J. M., Uchiyama T., Smith K. A., Waldmann T. A., Greene W. C. A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature. 1982 Nov 18;300(5889):267–269. doi: 10.1038/300267a0. [DOI] [PubMed] [Google Scholar]
  11. Mehra V., Convit J., Rubinstein A., Bloom B. R. Activated suppressor T cells in leprosy. J Immunol. 1982 Nov;129(5):1946–1951. [PubMed] [Google Scholar]
  12. Morimoto C., Reinherz E. L., Todd R. F., Distaso J. A., Schlossman S. F. Generation of antigen-specific suppressor cells in vitro in man. J Immunol. 1983 Sep;131(3):1209–1213. [PubMed] [Google Scholar]
  13. Mustafa A. S., Godal T. In vitro induction of human suppressor T cells by mycobacterial antigens. BCG activated OKT4+ cells mediate suppression of antigen induced T cell proliferation. Clin Exp Immunol. 1983 Apr;52(1):29–37. [PMC free article] [PubMed] [Google Scholar]
  14. Ohta N., Minai M., Sasazuki T. Antigen-specific suppressor T lymphocytes (Leu-2a+3a-) in human schistosomiasis japonica. J Immunol. 1983 Nov;131(5):2524–2528. [PubMed] [Google Scholar]
  15. Palacios R., Ivhed I., Sideras P., Nilsson K., Sugawara I., Fernandez C. Accessory function of human tumor cell lines. I. Production of interleukin 1 by the human histiocytic lymphoma cell line U-937. Eur J Immunol. 1982 Oct;12(10):895–899. doi: 10.1002/eji.1830121018. [DOI] [PubMed] [Google Scholar]
  16. Piccolella E., Lombardi G., Morelli R. Generation of suppressor cells in the response of human lymphocytes to a polysaccharide from Candida albicans. J Immunol. 1981 Jun;126(6):2151–2155. [PubMed] [Google Scholar]
  17. Piessens W. F., Partono F., Hoffman S. L., Ratiwayanto S., Piessens P. W., Palmieri J. R., Koiman I., Dennis D. T., Carney W. P. Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. N Engl J Med. 1982 Jul 15;307(3):144–148. doi: 10.1056/NEJM198207153070302. [DOI] [PubMed] [Google Scholar]
  18. ROSENTHAL S. R., LOEWINSOHNE, GRAHAM M. L., LIVERIGHT D., THORNE G., JOHNSON V. BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed. Pediatrics. 1961 Oct;28:622–641. [PubMed] [Google Scholar]
  19. Reem G. H., Yeh N. H. Interleukin 2 regulates expression of its receptor and synthesis of gamma interferon by human T lymphocytes. Science. 1984 Jul 27;225(4660):429–430. doi: 10.1126/science.6429853. [DOI] [PubMed] [Google Scholar]
  20. Shepard C. C., Walker L. L., Van Landingham R. M., Ye S. Z. Sensitization or tolerance to Mycobacterium leprae antigen by route of injection. Infect Immun. 1982 Nov;38(2):673–680. doi: 10.1128/iai.38.2.673-680.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Smith K. A., Lachman L. B., Oppenheim J. J., Favata M. F. The functional relationship of the interleukins. J Exp Med. 1980 Jun 1;151(6):1551–1556. doi: 10.1084/jem.151.6.1551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Stanford J. L., Shield M. J., Rook G. A. How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle. 1981 Mar;62(1):55–62. doi: 10.1016/0041-3879(81)90037-4. [DOI] [PubMed] [Google Scholar]
  23. Turcotte R., Forget A. Cutaneous unresponsiveness to Mycobacterium bovis BCG in intravenously infected mice. Infect Immun. 1983 Aug;41(2):453–461. doi: 10.1128/iai.41.2.453-461.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. UytdeHaag F., Heynen C. J., Ballieux R. E. Induction of antigen-specific human suppressor T lymphocytes in vitro. Nature. 1978 Feb 9;271(5645):556–557. doi: 10.1038/271556a0. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES